Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.

The advent of anti-TNF biological agents has been a massive advance in our treatment of RA and other inflammatory diseases. However, it is acknowledged that there are major drawbacks, the greatest being cost. There is, therefore, clearly a massive market for small molecular weight inhibitors that wo...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Foxwell, B, Andreakos, E, Brennan, F, Feldmann, M, Smith, C, Conron, M
Định dạng: Journal article
Ngôn ngữ:English
Được phát hành: 2003
Miêu tả
Tóm tắt:The advent of anti-TNF biological agents has been a massive advance in our treatment of RA and other inflammatory diseases. However, it is acknowledged that there are major drawbacks, the greatest being cost. There is, therefore, clearly a massive market for small molecular weight inhibitors that would achieve similar effects to those of the biological agents. However, the effectiveness and safety of the biological agents has raised a very large hurdle that will need to be overcome if the potential cost benefit of such an inhibitor is to be realised.